Treatment of hepatitis C virus infection for adults and children: Updated Swedish consensus recommendations

References

• Micallef JM, Kaldor JM, Dore GJ. Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies. J Viral Hepat. 2006;13:34–41.
   PubMed Web of Science ®Google Scholar
• Seeff LB. The history of the “natural history” of hepatitis C (1968–2009). Liver Int. 2009;29(Suppl 1):89–99.
   PubMed Web of Science ®Google Scholar
• Freeman AJ, Dore GJ, Law MG, et al. Estimating progression to cirrhosis in chronic hepatitis C virus infection. Hepatology. 2001;34:809–816.
   PubMed Web of Science ®Google Scholar
• Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology. 2004;127(5 Suppl 1):S35–50. PMID: 15508101.
   PubMed Web of Science ®Google Scholar
• Gerlach JT, Diepolder HM, Zachoval R, et al. Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance. Gastroenterology. 2003;125:80–88.
   PubMed Web of Science ®Google Scholar
• EASL Recommendations on Treatment of Hepatitis C 2015. J Hepatol. 2015;63:199–236.
   PubMed Web of Science ®Google Scholar
• Castera L. Noninvasive methods to assess liver disease in patients with hepatitis B or C. Gastroenterology. 2012;142:1293–1302 e4. doi: 10.1053/j.gastro.2012.02.017.
   PubMed Web of Science ®Google Scholar
• Sebastiani G, Halfon P, Castera L, et al. SAFE biopsy: a validated method for large-scale staging of liver fibrosis in chronic hepatitis C. Hepatology. 2009;49:1821–1827.
   PubMed Web of Science ®Google Scholar
• Batts KP, Ludwig J. Chronic hepatitis. An update on terminology and reporting. Am J Surg Pathol. 1995;19:1409–1417.
   PubMed Web of Science ®Google Scholar
• Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology. 1996;24:289–293.
   PubMed Web of Science ®Google Scholar
• Free medication for Hepatitis C. Iceland Monitor. 2015. Iceland Monitor, © 2015 Árvakur hf., Iceland. Available online at: http://icelandmonitor.mbl.is/news/politics_and_society/2015/10/07/free_medication_for_hepatitis_c/. Accessed 7 Oct 2015.
   Google Scholar
• Rembeck K, Lagging M. Impact of IL28B, ITPA and PNPLA3 genetic variants on therapeutic outcome and progression of hepatitis C virus infection. Pharmacogenomics. 2015;16:1179–1188.
   PubMed Web of Science ®Google Scholar
• Waldenstrom J, Nystrom K, Lagging M. Do variations in the ITPA gene determine the risk of hepatitis C virus relapse? Future Microbiol. 2014;9:1009–1012.
   PubMed Web of Science ®Google Scholar
• Rembeck K, Waldenstrom J, Hellstrand K, et al. Variants of the inosine triphosphate pyrophosphatase gene are associated with reduced relapse risk following treatment for HCV genotype 2/3. Hepatology. 2014;59:2131–2139.
   PubMed Web of Science ®Google Scholar
• Sarrazin C. The importance of resistance to direct antiviral drugs in HCV infection in clinical practice. J Hepatol. 24 Sep 2015. [Epub ahead of print]
   Google Scholar
• Waldenstrom J, Farkkila M, Rembeck K, et al. Short interferon and ribavirin treatment for HCV genotype 2 or 3 infection: NORDynamIC trial and real-life experience. Scand J Gastroenterol. 2016, Mar;51(3):337–343. doi: 10.3109/00365521.2015.1087588.
   PubMed Web of Science ®Google Scholar
• Lagging M, Langeland N, Pedersen C, et al. Randomized comparison of 12 or 24 weeks of peginterferon alpha-2a and ribavirin in chronic hepatitis C virus genotype 2/3 infection. Hepatology. 2008;47:1837–1845.
   PubMed Web of Science ®Google Scholar
• Lagging M, Langeland N, Pedersen C, et al. Weight-adjusted dosing of ribavirin and importance of hepatitis C virus RNA below 1000 IU/mL by day 7 in short-term peginterferon therapy for chronic genotype 2/3 hepatitis C virus infection. Hepatology. 2008;48:695. doi: 10.1002/hep.22450.
   PubMed Web of Science ®Google Scholar
• Lagging M, Alsio S, Hellstrand K, Norkrans G. Is HCV RNA analysis at day 7 cost-effective in deciding the duration of therapy in chronic HCV genotype 2/3 infection? J Hepatol. 2011;54:835–836; author reply 6–7.
   PubMed Web of Science ®Google Scholar
• Feld JJ, Kowdley KV, Coakley E, et al. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med. 2014;370:1594–1603.
   PubMed Web of Science ®Google Scholar
• Ferenci P, Bernstein D, Lalezari J, et al. ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med. 2014;370:1983–1992.
   PubMed Web of Science ®Google Scholar
• Zeuzem S, Jacobson IM, Baykal T, et al. Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med. 2014;370:1604–1614.
   PubMed Web of Science ®Google Scholar
• Sulkowski MS, Gardiner DF, Rodriguez-Torres M, et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med. 2014;370:211–221.
   PubMed Web of Science ®Google Scholar
• Lawitz E, Poordad FF, Pang PS, et al. Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial. Lancet. 2014;383:515–523.
   PubMed Web of Science ®Google Scholar
• Mizokami M, Yokosuka O, Takehara T, et al. Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trial. Lancet Infect Dis. 2015;15:645–653.
   PubMed Web of Science ®Google Scholar
• Afdhal N, Zeuzem S, Kwo P, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med. 2014;370:1889–1898.
   PubMed Web of Science ®Google Scholar
• Afdhal N, Reddy KR, Nelson DR, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med. 2014;370:1483–1493.
   PubMed Web of Science ®Google Scholar
• Kowdley KV, Gordon SC, Reddy KR, et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med. 2014;370:1879–1888.
   PubMed Web of Science ®Google Scholar
• Lawitz E, Sulkowski MS, Ghalib R, et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. Lancet. 2014;384: 1756–1765.
   PubMed Web of Science ®Google Scholar
• Kumada H, Chayama K, Rodrigues L Jr, et al. Randomized phase 3 trial of ombitasvir/paritaprevir/ritonavir for hepatitis C virus genotype 1b-infected Japanese patients with or without cirrhosis. Hepatology. 2015;62:1037–1046.
   PubMed Web of Science ®Google Scholar
• Lawitz E, Makara M, Akarca US, et al. Efficacy and Safety of Ombitasvir, Paritaprevir, and Ritonavir in an Open-Label Study of Patients With Genotype 1b Chronic Hepatitis C Virus With and Without Cirrhosis. Gastroenterology. 2015;149:971–980.
   PubMed Web of Science ®Google Scholar
• Poordad F, Hezode C, Trinh R, et al. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med. 2014;370:1973–1982.
   PubMed Web of Science ®Google Scholar
• Bourliere M, Bronowicki JP, de Ledinghen V, et al. Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS). Lancet Infect Dis. 2015;15:397–404.
   PubMed Web of Science ®Google Scholar
• Reddy KR, Bourliere M, Sulkowski M, et al. Ledipasvir and sofosbuvir in patients with genotype 1 hepatitis C virus infection and compensated cirrhosis: An integrated safety and efficacy analysis. Hepatology. 2015;62:79–86.
   PubMed Web of Science ®Google Scholar
• Pearlman BL, Ehleben C, Perrys M. The combination of simeprevir and sofosbuvir is more effective than that of peginterferon, ribavirin, and sofosbuvir for patients with hepatitis C-related Child's class A cirrhosis. Gastroenterology. 2015;148:762–770 e2; quiz e11–12.
   PubMed Web of Science ®Google Scholar
• Lagging M, Brown A, Mantry PS, et al. Grazoprevir plus peginterferon and ribavirin in treatment-naive patients with hepatitis C virus genotype 1 infection: a randomized trial. J Viral Hepat. 2015, Sep 10. [Epub ahead of print]. doi: 10.1111/jvh.12464.
   PubMedGoogle Scholar
• Lawitz E, Gane E, Pearlman B, et al. Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trial. Lancet. 2015;385:1075–1086.
   PubMed Web of Science ®Google Scholar
• Zeuzem S, Ghalib R, Reddy KR, et al. Grazoprevir-Elbasvir Combination Therapy for Treatment-Naive Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis C Virus Genotype 1, 4, or 6 Infection: A Randomized Trial. Ann Intern Med. 2015;163:1–13.
   PubMed Web of Science ®Google Scholar
• Gilead Sciences, Inc. Gilead announces svr12 rates from four phase 3 studies evaluating a once-daily, fixed-dose combination of Sofosbuvir (SOF) and Velpatasvir (VEL) (GS-5816) for the treatment of all six Hepatitis C Genotypes. 2015. Available online at: http://www.gilead.com/news/press-releases/2015/9/gilead-announces-svr12-rates-from-four-phase-3-studies-evaluating-a-oncedaily-fixeddose-combination-of-sofosbuvir-sof-and-velpatasvir-vel-gs5816-for-the-treatment-of-all-six-hepatitis-c-genotypes/. Accessed Sep 21, 2015.
   Google Scholar
• Zeuzem S, Dusheiko GM, Salupere R, et al. Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N Engl J Med. 2014;370:1993–2001.
   PubMed Web of Science ®Google Scholar
• Nelson DR, Cooper JN, Lalezari JP, et al. All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study. Hepatology. 2015;61:1127–1135.
   PubMed Web of Science ®Google Scholar
• Foster GR, Pianko S, Brown A, et al. Efficacy of Sofosbuvir plus Ribavirin with or without Peginterferon-alfa in patients with HCV Genotype 3 Infection and treatment-experienced patients with Cirrhosis and HCV Genotype 2 Infection. Gastroenterology. 2015;149:1462–70. doi: 10.1053/j.gastro.2015.07.043.
   Web of Science ®Google Scholar
• Hezode C, Asselah T, Reddy KR, et al. Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomised, open-label trial. Lancet. 2015;385:2502–2509.
   PubMed Web of Science ®Google Scholar
• Kohli A, Kapoor R, Sims Z, et al. Ledipasvir and sofosbuvir for hepatitis C genotype 4: a proof-of-concept, single-centre, open-label phase 2a cohort study. Lancet Infect Dis. 2015;15:1049–1054.
   PubMed Web of Science ®Google Scholar
• Smith MA, Mohammad RA. Ledipasvir-sofosbuvir for hepatitis C genotype 4 infection. Lancet Infect Dis. 2015;15:993–995.
   PubMed Web of Science ®Google Scholar
• Abergel A, Loustaud-Ratti V, Metivier A. Ledipasvir/sofosbuvir treatment results in high SVR rates in patients with chronic genotype 4 and 5 HCV infection. J Hepatol. 2015;62:S219.
   PubMedGoogle Scholar
• Gane EJ, Hyland RH, An D, et al. Efficacy of Ledipasvir and Sofosbuvir, with or without Ribavirin, for 12 weeks in patients with HCV Genotype 3 or 6 Infection. Gastroenterology. 2015;149:1454–1461.e1. doi: 10.1053/j.gastro.2015.07.063.
   PubMed Web of Science ®Google Scholar
• Ackefors M, Castedal M, Dahlgard O, et al. Peg-IFN and ribavirin treatment for recurrence of genotype 2 and 3 hepatitis C after liver transplantation. Infect Dis (Lond). 2015;47:209–217.
   PubMed Web of Science ®Google Scholar
• Hundemer GL, Sise ME, Wisocky J, et al. Use of sofosbuvir-based direct-acting antiviral therapy for hepatitis C viral infection in patients with severe renal insufficiency. Infect Dis (Lond). 2015;47:924–929.
   PubMed Web of Science ®Google Scholar
• Pockros PJ, Reddy KR, Mantry PS, et al. Safety of ombitasvir/paritaprevir/ritonavir plus dasabuvir for treating HCV gt1 infection in patients with severe renal impairment or end-stage renal disease: the RUBY-I study. J Hepatol. 2015;62:S257.
   PubMedGoogle Scholar
• Roth D, Nelson DR, Bruchfeld A, et al. Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study. Lancet. 2015;386:1537–1545. doi: 10.1016/S0140-6736(15)00349-9.
   Web of Science ®Google Scholar
• Bruchfeld A, Lindahl K, Schvarcz R, Stahle L. Dosage of ribavirin in patients with hepatitis C should be based on renal function: a population pharmacokinetic analysis. Ther Drug Monit. 2002;24:701–708.
   PubMed Web of Science ®Google Scholar
• Naggie S, Cooper C, Saag M, et al. Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1. N Engl J Med. 2015;373:705–713.
   PubMed Web of Science ®Google Scholar
• Wyles DL, Ruane PJ, Sulkowski MS, et al. Daclatasvir plus Sofosbuvir for HCV in Patients Coinfected with HIV-1. N Engl J Med. 2015;373:714–725.
   PubMed Web of Science ®Google Scholar
• Sulkowski MS, Eron JJ, Wyles D, et al. Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for hepatitis C in patients co-infected with HIV-1: a randomized trial. JAMA. 2015;313:1223–1231.
   PubMed Web of Science ®Google Scholar
• Lagging M. Impact of IL28B SNPs on therapeutic outcome and liver histology differs between hepatitis C virus genotypes. Pharmacogenomics. 2012;13:847–849.
   PubMed Web of Science ®Google Scholar
• Rembeck K, Alsio A, Christensen PB, et al. Impact of IL28B-related single nucleotide polymorphisms on liver histopathology in chronic hepatitis C genotype 2 and 3. PLoS One. 2012;7:e29370.
   PubMed Web of Science ®Google Scholar
• Rembeck K, Maglio C, Lagging M, et al. PNPLA 3 I148M genetic variant associates with insulin resistance and baseline viral load in HCV genotype 2 but not in genotype 3 infection. BMC Med Genet. 2012;13:82.
   PubMed Web of Science ®Google Scholar
• Ydreborg M, Westin J, Rembeck K, et al. Impact of Il28b-related single nucleotide polymorphisms on liver transient elastography in chronic hepatitis C infection. PLoS One. 2013;8:e80172.
   PubMed Web of Science ®Google Scholar
• Puoti M, Panzeri C, Rossotti R, Baiguera C. Efficacy of sofosbuvir-based therapies in HIV/HCV infected patients and persons who inject drugs. Dig Liver Dis. 2014;46(Suppl 5):S206–211.
   PubMedGoogle Scholar
• Lalezari J, Sullivan JG, Varunok P, et al. Ombitasvir/paritaprevir/r and dasabuvir plus ribavirin in HCV genotype 1-infected patients on methadone or buprenorphine. J Hepatol. 2015;63:364–369.
   PubMed Web of Science ®Google Scholar
• Dominguez A, Bruguera M, Vidal J, et al. Community-based seroepidemiological survey of HCV infection in Catalonia, Spain. J Med Virol. 2001;65:688–693.
   PubMed Web of Science ®Google Scholar
• Thomas SL, Newell ML, Peckham CS, et al. A review of hepatitis C virus (HCV) vertical transmission: risks of transmission to infants born to mothers with and without HCV viraemia or human immunodeficiency virus infection. Int J Epidemiol. 1998;27:108–117.
   PubMed Web of Science ®Google Scholar
• Ruiz-Extremera A, Munoz-Gamez JA, Salmeron-Ruiz MA, et al. Genetic variation in interleukin 28B with respect to vertical transmission of hepatitis C virus and spontaneous clearance in HCV-infected children. Hepatology. 2011;53:1830–1838.
   PubMed Web of Science ®Google Scholar